Arcellx Inc Stock Forecast:
The average analyst target price for Arcellx Inc over the next 12 months is USD 36.83, and the company has a strong buy rating among analysts. However, Stock Target Advisor‘s own analysis of the stock is neutral, based on 3 positive signals and 3 negative signals. Arcellx Inc’s current stock price is USD 30.25, which has increased by +0.83% over the past week, +8.00% over the past month, and +115.76% over the last year.
Analysts Coverage Change:
- H.C. Wainwright maintains a “Buy” rating for Arcellx Inc and lowers the price target to $40 from $42 on the company’s stock.
- SVB Leerink maintains an “Outperform” rating and raises the price target to $39 from $35.
Positive Fundamentals:
- High market capitalization: company is one of the largest in its sector and among the top quartile
- Superior risk adjusted returns: stock has performed well compared to sector peers for a hold period of at least 12 months and is in the top quartile
- Low volatility: stock’s annual returns have been stable and consistent compared to sector peers for a hold period of at least 12 months and is in the top quartile
- Stability is good for limiting risk, but it can also limit returns.
Negative Fundamentals:
- Stock is overpriced compared to book value.
- Trading high compared to peers’ median on a price to book value basis.
- Company had negative total cash flow in the most recent four quarters.
- Company had negative total free cash flow in the most recent four quarters.
FA Score (Fundamental Analysis):
The fundamental analysis of Arcellx Inc. is “Neutral” with a FA score of 5 out 0f 10, where 0 is very bearish and 10 is very bullish.
About Arcellx Inc.:
Arcellx is a biotechnology company focused on developing immunotherapies for cancer and other incurable diseases. Its lead product candidate, CART-ddBCMA, is currently in phase 1 clinical trial for treating relapsed or refractory multiple myeloma. Additionally, the company is developing immunotherapeutic combinations such as ACLX-001, ACLX-002, and ACLX-003 to treat various types of cancer. Arcellx has a strategic alliance with Kite for co-developing and co-commercializing CART-ddBCMA. The company was formerly known as Encarta Therapeutics and is headquartered in Gaithersburg, Maryland.
